Theralogics is focused to the discovery and development of NF-B-related discoveries and technologies. Theralogics has licensed key NF-B-related technologies from both UNC and Yale and has built a unique national network of scientific collaborators who are able to quickly test discoveries and technologies in a series of highly relevant models of disease. Using this model, Theralogics has already made important discoveries in several disease areas, most especially in recent collaborative work done with Dr. Denis Guttridge of the Ohio State University in the field of Muscular Dystrophy. Theralogics, either directly or in collaboration with members of its investigator network, maintains NF-B-related research programs in a range of human disease areas, including the following in Cardiovascular - cardiac hypertrophy; Dermatology - dermatitis and psoriasis; Gastroenterology - colitis and other inflammatory disorders; Musculoskeletal - muscular dystrophy and cachexia; Neurology - spinal cord injury; Oncology - tumor-reduction therapy, chemopotentiation and graft vs. host disease; Respiratory - asthma; Rheumatology - arthritis; Virology - SARS
